학술논문
Immune correlates analysis of the PREVENT-19 COVID-19 vaccine efficacy clinical trial
Document Type
article
Author
Youyi Fong; Yunda Huang; David Benkeser; Lindsay N. Carpp; Germán Áñez; Wayne Woo; Alice McGarry; Lisa M. Dunkle; Iksung Cho; Christopher R. Houchens; Karen Martins; Lakshmi Jayashankar; Flora Castellino; Christos J. Petropoulos; Andrew Leith; Deanne Haugaard; Bill Webb; Yiwen Lu; Chenchen Yu; Bhavesh Borate; Lars W. P. van der Laan; Nima S. Hejazi; April K. Randhawa; Michele P. Andrasik; James G. Kublin; Julia Hutter; Maryam Keshtkar-Jahromi; Tatiana H. Beresnev; Lawrence Corey; Kathleen M. Neuzil; Dean Follmann; Julie A. Ake; Cynthia L. Gay; Karen L. Kotloff; Richard A. Koup; Ruben O. Donis; Peter B. Gilbert; Immune Assays Team; Coronavirus Vaccine Prevention Network (CoVPN)/2019nCoV-301 Principal Investigators and Study Team; United States Government (USG)/CoVPN Biostatistics Team
Source
Nature Communications, Vol 14, Iss 1, Pp 1-15 (2023)
Subject
Language
English
ISSN
2041-1723
Abstract
Authors have previously reported on the efficacy and safety of the recombinant spike protein nanoparticle vaccine, NVX-CoV2373, in healthy adults. In this work, they assess anti-spike binding IgG, anti-RBD binding IgG and neutralising antibody titer as correlates of risk and protection against COVID-19.